Envisioning health research driven by patients and fueled by mobile apps, interoperable electronic health records, real world data and genetics, National Institutes of Health (NIH) Director Francis Collins Wednesday painted a future of possibilities for new cures and more informed treatment as he opened the first public meeting on the president's Precision Medicine Initiative. Read More
DUBLIN – Glaxosmithkline plc paid $190 million to acquire Glycovaxyn AG outright in a deal that values the Swiss vaccine developer at $212 million. Read More
Taken from a standpoint that was hysterical to one that's more historical, Wall Street began warming up to Keryx Biopharmaceuticals Inc.'s sales of ferric citrate. Read More
LONDON – A £200 million (US$304.7 million) UK national initiative in precision medicine, due to get off the ground in April, is to be chaired by Richard Barker, a former head of the Association of the British Pharmaceutical Industry (ABPI). Read More
TAIPEI, Taiwan – Biologic drugs are so difficult to make that they are almost impossible to counterfeit, but that does not mean that they are immune to the onslaught of fake products. And yet clamping down on fake biologics can be hard and expensive to do, not to mention that simply identifying fake products after they have been used can be quite difficult. Read More
NEW YORK – The 17th annual BIO CEO & Investor Conference wrapped up, with the Biotechnology Industry Organization reporting more than 2,220 partnering meetings over the two-day event and a session schedule that hit all the big topics as industry experts offered up insight and lessons learned. Read More
HYDERABAD, India – A slew of measures to cut down the approval times for clinical trials, streamline regulatory guidelines and strengthen safety is helping India regain some traction as a site for trials – traction lost in the years through 2013. Read More
Seattle Genetics Inc., of Bothell, Wash., reported that for the year ended Dec. 31, 2014, total revenues were $286.8 million compared to $269.3 million in 2013. Adcetris (brentuximab vedotin) net sales for the year were $178.2 million. Read More
Cidara Therapeutics Inc., of San Diego, said it completed a $42 million series B financing that included both new and existing investors participating. Read More
Nanosmart Pharmaceuticals Inc., of Laguna Hills, Calif., said it received FDA orphan drug designation for one of its lead candidates, antinuclear antibody conjugated liposomal doxorubicin. Read More
Edge Therapeutics Inc., of Berkeley Heights, N.J. reported that its ongoing phase I/I study of the company's lead candidate, EG-1962 for patients that have suffered a subarachnoid hemorrhage from a ruptured brain aneurysm, has completed enrollment and yielded safety and 90-day functional outcome efficacy data for 24 patients. Read More
Pfizer Inc., of New York, teamed up with the Alzheimer's Drug Discovery Foundation (ADDF) by way of Pfizer's Centers for Therapeutic Innovation (CTI) to advance the development of new small-molecule drugs for Alzheimer's disease and related dementias. Read More
Baxter International Inc., of Deerfield, Ill., said that patients in the twice-weekly prophylaxis arm of a pivotal phase III trial of its extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia, BAX 855, experienced a 95 percent reduction in median annualized bleed rate as compared to those in the on-demand arm (1.9 vs. 41.5, respectively). Read More
